Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

134
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
134
Mechanistic Models: Overview of Compartment Models01:21

Mechanistic Models: Overview of Compartment Models

562
Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
562
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model01:14

Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model

132
The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A...
132
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.8K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.8K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

472
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
472
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

323
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
323

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a discrete choice experiment design to explore how patient characteristics influence preferred fixation method in total hip replacement in the UK.

BMC musculoskeletal disorders·2026
Same author

What influences UK-practising consultant hip surgeons' decision-making about implant fixation? An interview study.

BMJ open·2026
Same author

Finding the Goldilocks zone: Modulating glycoprotein cleavage and fusogenicity optimizes the efficacy of a candidate Crimean-Congo hemorrhagic fever virus vaccine.

bioRxiv : the preprint server for biology·2026
Same author

Circulating lipids are related to longitudinal changes of ATN biomarkers for Alzheimer's disease.

Molecular psychiatry·2026
Same author

Crimean-Congo hemorrhagic fever virus protein GP38 from isolate M18-China confers broad immunological breadth.

Research square·2026
Same author

Association between surgeon experience, level of supervision, and outcomes after hip fracture.

Bone & joint open·2026

Related Experiment Video

Updated: Apr 21, 2026

Author Spotlight: Advancing Cell Membrane Biophysics - Exploring Interactions and Challenges Through Experimental and Computational Approaches
07:31

Author Spotlight: Advancing Cell Membrane Biophysics - Exploring Interactions and Challenges Through Experimental and Computational Approaches

Published on: September 1, 2023

3.5K

Virtual Systems Pharmacology (ViSP) software for simulation from mechanistic systems-level models.

Sergey Ermakov1, Peter Forster2, Jyotsna Pagidala3

  • 1Exploratory Clinical and Translational Research, Bristol-Myers Squibb Princeton, NJ, USA.

Frontiers in Pharmacology
|November 7, 2014
PubMed
Summary

A new integrated software platform enables scientists to run large-scale pharmacology simulations using models from various tools. This system-agnostic application streamlines drug development by compiling models into standalone executables, reducing time and IT costs.

Keywords:
metabolic diseases modelmodel development softwarequantitative systems pharmacologysimulation experimentsystem-level mechanistic modelsvirtual patient

More Related Videos

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
05:47

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox

Published on: August 28, 2019

14.9K
Author Spotlight: Streamlining Visual Dynamics to Simplify Molecular Dynamics Simulations Using Gromacs
05:00

Author Spotlight: Streamlining Visual Dynamics to Simplify Molecular Dynamics Simulations Using Gromacs

Published on: August 9, 2024

2.1K

Related Experiment Videos

Last Updated: Apr 21, 2026

Author Spotlight: Advancing Cell Membrane Biophysics - Exploring Interactions and Challenges Through Experimental and Computational Approaches
07:31

Author Spotlight: Advancing Cell Membrane Biophysics - Exploring Interactions and Challenges Through Experimental and Computational Approaches

Published on: September 1, 2023

3.5K
In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
05:47

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox

Published on: August 28, 2019

14.9K
Author Spotlight: Streamlining Visual Dynamics to Simplify Molecular Dynamics Simulations Using Gromacs
05:00

Author Spotlight: Streamlining Visual Dynamics to Simplify Molecular Dynamics Simulations Using Gromacs

Published on: August 9, 2024

2.1K

Area of Science:

  • Pharmacology
  • Computational Biology
  • Software Engineering

Background:

  • Drug development relies on system-level pharmacology models, often requiring multiple software tools.
  • Using diverse modeling software can increase development time, IT expenses, and complexity.
  • A unified platform is needed to manage and execute simulations from various modeling tools.

Purpose of the Study:

  • To develop a single, versatile software platform for setting up and running large-scale simulations.
  • To enable the use of models developed with different software tools within a unified environment.
  • To streamline the drug development process through integrated systems pharmacology modeling.

Main Methods:

  • Developed a workflow and software platform to compile model files into self-contained, executable files.
  • Ensured model specifics are preserved by using all model parameters as executable inputs.
  • Implemented a model-agnostic, therapeutic area-agnostic, web-based application with a database back-end.
  • Designed a configurable user interface and a database for managing models, virtual patients, settings, and results.
  • Demonstrated the platform using a metabolic disease systems pharmacology model for antidiabetic drug simulation.

Main Results:

  • Successfully created a unified platform that integrates models from different software origins.
  • The platform allows for model-agnostic and therapeutic area-agnostic large-scale simulations.
  • Demonstrated the platform's capability with a type 2 diabetes mellitus model simulating metformin and fasiglifam effects.
  • The system supports multiple users in configuring, managing, and executing simulations.

Conclusions:

  • The developed platform effectively consolidates diverse pharmacology modeling tools into a single, efficient system.
  • This approach reduces dependency on specific software, lowers IT costs, and accelerates model development.
  • The platform offers a scalable and adaptable solution for complex systems pharmacology simulations in drug development.
  • Its successful demonstration in a metabolic disease context highlights its potential for broader application.